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Abstract
Blood pressure management in the acute period following spinal cord injury is a critical
concern; one that anesthesia and critical care providers are often able to directly measure and
regulate. It has been hypothesized that supraphysiologic blood pressure maintenance during this
acute phase may improve recovery, however there is limited high-quality evidence to reinforce
and guide management. Based on included prospective and retrospective studies, which provide
the highest level of evidence available, The American Association of Neurologic Surgeons does
provide the following level III recommendation: MAP goals of 85–90 mm Hg for 5–7 days postinjury should be considered. With regard to the optimal vasopressor, dopamine should be
avoided. Norepinephrine should be considered as a first-line agent for cervical and upper
thoracic spinal cord injuries, given evidence that it has a lower risk profile than dopamine. For
injuries in the mid to lower thoracic spine, norepinephrine or phenylephrine should be considered
as first-line agents. In summary, blood pressure management should not be overlooked and
proper utilization could result in significant improvements in quality of life and hope for
recovery.

Introduction
The management of spinal cord injuries (SCI) presents a unique set of challenges to
anesthetists and is an area of ongoing research and best-practice development. One focus of
ongoing research is the utilization of arterial catheters to measure and maintain blood pressure at
supraphysiologic levels immediately post-injury to promote adequate end-tissue perfusion as
well as the removal of accumulating cellular waste products at the site of injury. This technique
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has shown benefit, though detailed interactions between vasopressor utilization and outcomes
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have thus far been difficult to identify due to the relatively low number of severe spinal cord
injuries across the population (Kepler et al., 2015). As a result, strong recommendations by
governing bodies have not been forthcoming. The American Association of Neurological
Surgeons currently lists MAP maintenance >90mmHg as a level III recommendation, indicating
that this practice is supported by available data, though the evidence is lacking and future clinical
research is indicated. The goal of this project is thus to review both historic and current literature
to find cases of SCI where supraphysiologic MAP is beneficial in promoting enhanced recovery.
A secondary goal of this literature review is to uncover anesthetic implications for blood pressure
management of patients with SCI. Cardiovascular complications after spinal cord injury often
necessitate the use of vasopressors for management and the ideal vassopressor for use in this
population is controversial and often difficult to study. This paper aims to highlight the specific
studies utilized for ongoing recommendations of MAP maintenance in patients with spinal cord
injuries and also evaluate areas that supraphysiologic MAP therapy may not be indicated or
provide limited clinical benefit. This paper will also elucidate several studies that evaluate the
efficacy of select vasopressor agents, as there is data that suggests certain agents may provide
improved outcomes.

Physiology of augmented MAP therapy
Multiple animal models and human studies dealing with neural tissue contribute to the
hypothesized physiology supporting MAP therapy in SCI patients. Maintenance of elevated
MAP goals seems to provide a neuroprotective effect via two unique pathways (Readdy, W.
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Dall, S. 2016). The first is through mitigating episodes of hypotension commonly experienced in
these patients. This hypotension can by systemic, as induced by neural trauma to sympathetic
neurons that innervate the heart and blood vessels thus leading to erratic blood pressure control.
Hypotension may also be highly localized to the level of trauma, as bony impingement of
neurovascular bundles is often a component of traumatic spinal cord injuries. This often requires
surgical decompression; though artificially elevated blood pressure may enhance blood flow
even through neural vascular beds that might otherwise be compromised at unaltered blood
pressures. This systemic and localized hypotension is further compounded by the frequent
occurrence in many high level SCI patients of sever hemodynamic instability induced by
neurogenic shock and autonomic dysreflexia.
The first goal of MAP therapy can thus be stated as maintaining adequate systemic

perfusion and oxygen delivery to highly dependent neural tissue. Without this perfusion, hypoxia
and inadequate nutrient delivery to the injured site can impair or even halt natural cellular
function. The presence of hypoxia at the injury site can lead to rapid failure of the Kreb’s cycle
and impair neuronal maintenance of ATP levels with further damage occurring rapidly. The
second goal of neuroprotection is the utilization of enhanced blood flow through neural-vascular
beds to increase mobilization and clearance of waste products. By increasing cytokine and other
inflammatory marker clearance it may be possible to limit excessive inflammatory damage and
secondary injury to the spinal cord in the days and weeks following spinal cord injury. There
currently exist multiple other intervention modalities directed at promoting cellular oxygen
utilization and waste product clearance such as steroid therapy and periods of hypothermia that
are outside of the scope of this paper.
Background
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efficacious in brain injury patients, but it’s utilization in SCI was not widely popularized until
Vale et al. (1997) published an article evaluating combined medical and surgical treatment after
acute spinal cord injury. The study hypothesized that tightly controlled blood pressure
augmentation would aid in maintaining spinal cord blood flow and prevent some effects of
secondary injury. The study design prospectively examined 64 SCI patients starting in 1992 with
trauma ranging from C1-T12 who were treated with volume resuscitation and pharmacologic
blood pressure augmentation to maintain supraphysiologic MAP goals > 85 mmHg for a
minimum of 7 days post-injury. All patients started treatment within 36 hours of initial injury.
There was no control group for this study, as severe SCI are a relatively rare occurrence and
neurologic deficits and recovery vary widely between patients making direct comparison
difficult. Outcomes were then compared to expected results on the basis of recovery experience
in patients with SCI who had been managed without aggressive volume and blood pressure
augmentation. All patients were managed in an ICU with Swan-Ganz and arterial blood pressure
catheters for accuracy of results and precision management. Goal MAP was achieved with
intravenous crystalloids, colloids, and vasopressors. Many of these patients also received
decompression, stabilization, and fusion in select cases.
Results were stratified into complete SCI and incomplete SCI to differentiate between
severity. As might be expected due to the traumatic nature of injury, neurologic recovery
throughout the study group was variable and often incomplete; though this study did supply
results that exceeded expected outcomes based on historic projections of SCI recovery. Results
were reported in both American Spinal Injury Association (ASIA) grade (see table below for full
results) and motor index score (MIS). Results indicate that incomplete SCI treated with MAP
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goals resulted in clinical improvement for 92% of patients studied after 12 months. 60% of
patients with complete cervical spinal cord injuries improved by at least one ASIA grade at 1
year follow up (see Appendix A for grade system). Please see table 1 for data pertaining to
improvement of ASIA score from initial injury to 12 month follow-up. Of note, many of these
patients continued to improve after this 12 month assessment and none lost neurologic function
or increased their ASIA grade during the course of the study.
TABLE 1
Outcome improvement in 64 patients with spinal cord injury according to ASIA
Impairment Scale*
Outcome ASIA Grade at 12-Mo Follow Up
Initial
ASIA
Grade

No. of
Patients

A

B

C

D

E

cervical cord injury
A

10

4

1

2

3

—

B

6

—

1

1

4

—

C

8

—

—

1

4

3

D

11

—

—

—

6

5

thoracic cord injury
A

21

14

2

3

2

—

B

5

—

1

2

2

—

C

1

—

—

—

1

—

D

2

—

—

—

—

2

6
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*

No patient had an initial ASIA grade of E. — = not applicable.
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Legend: numbers represent patient n, letters represent ASIA grade at initial presentation (y axis)
and at 12 month follow up (x axis)

In addition, the study did not show an increased instance of hypertensive hemorrhage, stroke,
myocardial infarction, or death in the mean 17 month tracking period after patient injury
(Subsequent studies evaluated with more sensitive measures of complications do show increased
morbidity with vasopressor utilization). Based on the outcomes of the study, it was concluded by
the ASIA that aggressive cardiopulmonary resuscitation efforts result in improved neurologic
outcomes in patients with acute SCI. The results of Vale et al formed the basis for the 2012
Level III recommendation from the American Association of Neurologic Surgeons (AANS)
regarding cardiopulmonary resuscitation in SCI. These guidelines state that hypotension should
specifically be avoided and a goal MAP of 85-90mmhg should be targeted in the first 5-7 days
after acute SCI. These guidelines have since formed the basis of care for many facilities despite
the fact that subsequent studies have been unable to advance this level of recommendation.
Authors of Vale et al. state that the ideal supraphysiologic MAP to maintain has yet to be
established, and the ideal vassopressor for this application requires additional investigation.
Two other studies require brief mention as being fundamental articles establishing
supraphysiologic MAP as a possible intervention for SCI management. Levi et al.
(1993) performed a prospective study in which the authors described the outcomes of a group of
50 patients who underwent spinal immobilization or fixation as indicated, with their post-injury
care at a trauma center between 1990 and 1991. A MAP goal higher than 90 mm Hg was
maintained with fluids and dopamine for 7 days post injury. Some patients required the addition
of dobutamine for additional support. 82% of patients showed stable or improved neurological
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that pursuing aggressive MAP goals was feasible and of relatively low risk. Wolf et al.
(1991) independently conducted a retrospective review of data for 52 patients who sustained a
SCI between 1987 and 1990 due to bilateral facet dislocation. The patients were managed after
decompression with an MAP goal greater than 85 mm Hg for 5 days. Twenty-two patients
underwent follow-up for at least 12 months post-injury and all of these patients had stability or
improvement in their functional grade. Neither of these last two studies included comparison
groups, though they provided a foundation for subsequent investigation. In summary, these
studies all point to the likelihood that increased MAP >85 supports long-term recovery, but none
have the power to state it definitively.

Review of recent literature
Subsequent studies have continued to reinforce the hypothesis of earlier investigations:
augmented MAP seems to improve long term outcomes. The papers included here will help to
elucidate the subtleties of this hypothesis through unique populations and study designs.
Cohn et al. (2010) retrospectively reviewed 17 patients at Santa Clara medical center
presenting with tetraplegia between 2000 and 2006. MAP recording was performed at least 3
times daily for 7 days postinjury. The authors estimated the amount of time patients spent with
MAP above thresholds of 85, 75, and 65 mm Hg. The authors estimated that patients had MAP
values greater than 85 mm Hg 33% of the time, greater than 75 mm Hg 65% of the time, and
greater than 65 mm Hg 91% of the time. They also showed that the percent of time with a MAP
of ≤70 mm Hg was inversely correlated to motor score gains. The correlation was insignificant
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for time spent at a MAP of >75mm Hg, thus setting an upper limit of benefit achieved with MAP
augmentation for the purpose of this study. Neurological outcome as measured by AIS grade and
ASIA motor score was not found to be related to duration of time at a goal of MAP greater than
75 or 85 mm Hg. This study importantly displays that there seems to be no benefit for
maintaining MAP at values greater then 75, though it does not reveal what deleterious effects
hypotension may have.
Hawryluk et al. (2015) retrospectively reviewed MAP data for 74 SCI patients who
underwent post-injury treatment between 2005 and 2011 at San Francisco General Hospital and
were managed with a MAP goal greater than 85 mm Hg for 5 days post injury. All patients were
managed with arterial catheters and data was collected automatically every 1 minute during their
intensive care stay. The relationship between these values as well as the proportion of MAP
recordings below 85mmHg was studied. The authors found that about 25% of all MAP’s for the
first 5 days post injury were lower than the goal. The patients who exhibited the greatest
neurological improvement as measured by AIS grade had fewer MAP measurements lower than
the goal compared with patients without neurological improvement. Thus this study displays that

for their population roughly 1/4th of MAP values were lower than 85mmHg and that patients who
displayed greater recovery had fewer episodes of hypotension. While this does not give concrete
hypotensive values to avoid, it does provide evidence that hypotension may be associated with
poor prognosis.
The authors reported that their data suggests that a MAP of 70–75 mmHg appeared to be
the threshold at which neurological benefit is correlated with MAP goals. In addition, the authors
noted that the first 2–3 days after injury with elevated MAP correlated most strongly with
recovery. This correlation between MAP and eventual recovery decreased in strength over the
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first week post-injury. Despite these findings, there is still not enough evidence to prove a causal
relationship between recovery and blood pressure management, though a strong correlation does
exist. The study does support that duration of hypotension may be more important than average
MAP. Another important finding from the study is the correlation that MAP thresholds >85 are
associated with higher degrees of neurological recovery.
Inoue et al. (2014) retrospectively reviewed 131 patients who were admitted with SCI
between 2005 and 2011 at a level 1 trauma center and received vasopressors to maintain MAP
goals of higher than 85 mmHg. Although this was a retrospective review, the MAP data were
collected prospectively. This patient population was also analyzed in the studies by Hawryluk et
al. and Catapano et al., which are also reviewed in this paper. MAP goals were maintained for 5
days before being relaxed to lower levels. AIS grades were collected as outcome measures up
until the time of discharge from the hospital; no association was found between neurological
outcome and the use of vasopressors to maintain MAP goals. There was no comparison or
control group. Thus this study is equivocal in its findings and does not show any link between
MAP goals and recovery.
Catapano et al. (2016) retrospectively reviewed 62 patients who presented between 2005
and 2011 at San Francisco General Hospital with traumatic SCI. Of note, this patient population
was also previously studied by Inoue et al as well as by Hawryluk et al., both of which are
summarized above. This further highlights the difficulty of finding even moderately sized novel
study groups for human study of SCI. The authors compared the average MAP as well as the
proportion of MAP lower than 85 mm Hg with their outcomes, as measured by comparing AIS
grades at presentation and discharge. MAP was analyzed only for the first 3 days after injury.
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than 85 mm Hg in patients presenting with AIS Grade A, B, or C. This study thus flushed out
two new points: that augmented blood pressure within just the first 3 days significantly
correlated BP and neurologic improvement (thus seeming to indicate with no upper limit that
higher MAP is better) and also that patients who initially presented with and AIS grade of D (see
appendix A) did not display any change in neurologic improvement with augmented MAP. This
may be because these patients with less severe spinal trauma are much less likely to have periods
of hypotension.
Dakson et al. (2017) retrospectively reviewed 94 patients (after excluding 6 deaths and 64
cases of inappropriately coded SCI patients) who presented with SCI at an acute trauma center in
Halifax Nova Scotia between 2006 and 2010. Their study sought to evaluate MAP management
and timing of surgical decompression, thus providing an interesting set of data with two
variables.
They found remarkably strong data that patients with a MAP <85mm Hg for at least 2
consecutive hours during the 5 day period postinjury were 11 times less likely to have an
improvement in their American Spinal Injury Association (ASIA) grade when compared with
patients who’s MAP was ≥85mm Hg (p=0.006). This association was found to be independent of
early surgery or the severity of SCI. That said, at a mean of 252 days post-injury, a significantly
greater proportion of SCI patients treated with early surgical decompression ( < 24 hours) had
some degree of neurologic improvement (P=0.031). Serial hourly MAP were collected for 50 of
these patients. MAP lower than 85 mm Hg for more than 2 consecutive hours in the 5 days post
injury was defined as suboptimal BP management. Finally their group also found that MAP
treatment for 7 days as opposed to previous recommendations of 5-7 was associated with
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MAP ≥ 85 mm Hg for 7 days post-injury.
In summary, maintenance of mean arterial blood pressure between 85 and 90mm Hg for
the first 7 days following an acute spinal cord injury is almost universally recommended, though
one studies show no benefit with maintaining MAP >75 (Hawryluk et al, 2015). That said,
another study (Dakson et al, 2017) showed that MAP values <85mmHg for >2 hours were
associated with poor outcomes. Future studies may show that these values are actually
complementary and represent relative upper and lower limits of blood pressure control.
Subsequent studies will need to tease out the variability seen between these and other studies.
Research is ongoing in this field and the recommendations of the American Association of
Neurologic Surgeons continue to evolve as further research displays the areas where
supraphysiologic MAP can provide the greatest benefit.

Spinal cord damage and vasopressor utilization in animal studies
Animal models offer a unique way to study SCI and interventions that would be
otherwise impossible in human subjects for technical or ethical considerations. In regards to
spinal cord damage, there have been many animal studies that contribute to our knowledge base.
For this reason most of the existing knowledge regarding SCI pathology and potential
interventions are derived from animal studies. A review of over 2200 articles (Sharif-Alhoseini
et al, 2017) provides a wealth of data about the kinds of research that has been done in this field.
They showed that the most common spinal region studied was thoracic (1790 articles, 81%)
followed by cervical (265 articles, 12%), Lumbar (113 articles, 51%), sacral (16 articles, .07%),
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unknown (64 articles, 2.9%), and other (16 articles, .7%). Their review showed that most studies
were classified as mechanical traumatic injury (94.5%) as opposed to non-mechanical injury
(5.5%) and also that the mostly widely studied species were rodents (92%). This review is

significant to the research topic of MAP control as it highlights how few studies are performed in
animals to evaluate the impact of MAP control following SCI. Of all included studies, only 61
(2.8%) included any sort of cardiovascular evaluation. One reason for this is that rodents
represent a poor model for arterial blood pressure monitoring based on their small size. Another
reason that few animal models have evaluated MAP control is the overall low number of studies
evaluating cervical cord injury, as this is the group most likely to benefit from tight blood
pressure control. Nevertheless, there are several animal studies that have significantly
contributed to this area of investigation.
One such animal study, published in June 2018 after the above review, evaluates the
comparison between norepinephrine (NE) and phenylephrine (PE) for augmenting spinal cord
perfusion in a porcine model of spinal cord injury (Streijger et al., 2018). This article highlights
the pharmacologic properties and potentially different effects these medications have on spinal
cord blood flow (SCBF), oxygenation (P02), and downstream metabolites after injury. The
model selected was a thoracic spinal cord contusion/compression at T10 with measurement of
the spinal cord adjacent to the injury with a microdialysis probe inserted into the spinal cord to
measure intraparenchymal SCBF, P02, hydrostatic pressure, and metabolism. Two sites were
used for measurement including a proximal site 2mm from the lesion and a distal site 22mm
from the lesion. The pigs were randomized to receive either NE or PE for MAP elevations of
20mmHg, or no MAP augmentation. Of note, neither NE nor PE showed significant
improvement in SCBF during cord compression. Following decompression however, NE
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Both NE and PE were associated with a gradual decrease in the lactate to pyruvate ratio after
decompression. This study also revealed that PE was associated with greater hemorrhage through
the injury site than in control animals. This study points to utilization of NE over PE for
promotion of blood flow and oxygenation thus providing a physiologic rational for the selection
of a vasopressor in this population. Unfortunately there still exists a gap between human and
animal models and applying this data to human patients requires a leap of inference.

Vasopressor selection in human models
Given that hypotension is strongly correlated with poor outcomes in SCI patients it
follows that vasopressor management would be an important inclusion in care for these patients.
Selection of vasopressors is often subject to particulars of the patient condition and is generally
continued from emergency management. Data on selection of vasopressor for best efficacy in
cases of spinal cord injury is lacking and difficult to collect. Human studies are lacking in terms
of randomized control trials, but there are studies selectively comparing unique vasopressors to
achieve specific MAP goals. One such study by Altaf et al. (2016) looked at the differential
effects of norepinephrine (NE) and dopamine (DP) on cerebrospinal fluid pressure and spinal
cord perfusion pressure (SCPP) after acute human spinal cord injury. 11 patients over the age of
17 with cervical or thoracic injury were enrolled in the study. NE and DP were evaluated in a
crossover procedure to directly compare their effect on intrathecal pressure (ITP). ITP, MAP,
and heart rate were continuously monitored in an intensive care unit where the study took place.
SCPP was calculated as the difference between MAP and ITP. Results showed no difference in
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MAP between NE and DP (84mmHg for both; P.033), though ITP was significantly lower with

the use of NE (17 mmHg vs 20 mmHg DP, P<.001). This resulted in a net increase SCPP during
NE infusion when compared to DP infusions (67 mmHg vs 65mmHg, P=.0049). These results
seem to indicate that NE provides a more favorable environment for neural recovery as opposed
to DP.
Another study that highlights the unique differences among available vasopressors is a
2015 study by Readdy et al. titled complications and outcomes of vasopressor usage in acute
traumatic central cord syndrome (ATCCS). This retrospective cohort analysis looked at 34
patients with ATCCS who received vasopressors to maintain blood pressure at a single level 1
trauma center. Dopamine (DP) and phenylephrine (PE) were utilized and analyzed for
complications during treatment. Results showed that DP was the most commonly utilized
primary vasopressor (91%) with PE being used in 65% of patients. Vasopressors were
administered to a goal of 85 MAP for a mean of 101 hours and notably all patients improved by
a median of 1 ASIA grade regardless of vasopressor utilized. There was however no observed
relationship between the timing of surgical intervention and complication rate. Cardiogenic
complications associated with vasopressor usage were noted in 68% of patients who received
dopamine and 46% of patients who received phenylephrine (P=.105). These complications
included atrial fibrillation (5 in DP group, 0 in PE group), Tachycardia (9 in DP group, 3 in PE
group), Bradycardia (4 in DP group, 7 in PE group), and ventricular tachycardia (3 in DP group,
0 in PE group). Please see table 4 below for complications. Of note, over 50% of these patients
experienced some sort of cardiovascular complication, highlighting the fact that blood pressure
augmentation is not a benign intervention.
TABLE 4.
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Specific complication rates by individual vasopressor
No. of Patients (%)*
Complication

Dopamine

Phenylephrine

Patients w/ complications

21 (67.74)

10 (45.45)

Patients w/ multiple
complications

2 (6.45)

1 (4.54)

Atrial fibrillation

5 (16.13)

0 (0)

Tachycardia (HR >130 bpm)

9 (29.03)

3 (13.64)

Bradycardia (HR<50bpm)

4 (12.90)

7 (31.82)

Ventricular tachycardia

3 (9.68)

0 (0)

2 (6.45)

1 (4.54)

Troponin levels
HR = heart rate.
*

Percentages are based on the number of patients per category.

Legend- number and percentages(%) of patients experiencing complications with dopamine vs
phenylephrine

Of note, patents over the age of 55 did show statistically significant increases in the complication
rates when DP was used when compared with PE. This study thus potentially supports the
restriction of DP to patients less then 55 years of age. The low N number and retrospective
nature of this study do limit the findings significantly and prevent several conclusions from
reaching statistical significance. That said, it is still clear from the results and table 4 that
vasopressor selection directly impacts complications rates and that the unique profiles of
commercially available agents should be considered before utilizing a particular vasopressor.

Potential risk with hypertensive therapy and vasopressor utilization.
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complications from vasopressor use. A review by Inoue et al. (2014) evaluated the complications
associated with vasopressor administration for the support of MAP goals in a cohort of 131 SCI
patients. In this review, dopamine was found to be the most commonly utilized vasopressor
(48%) followed by phenylephrine (45%), norepinephrine (5%), epinephrine (1.5%), and
vasopressin (.5%). Logistic regression analysis demonstrated that complications due to
vasopressors were independently associated with the overall usage of dopamine and
phenylephrine, age >60, and complete SCI. The review found no difference in neurological
improvement with either dopamine or phenelephrine when compared to one another. What the
study did find to be associated with improved outcome was surgery <24 hours after SCI, or an
incomplete SCI as the initial injury. This study does not have the power to show that
vasopressors are associated with worse outcomes, but it does correlate vasopressor use with
increased complication rates that might mitigate the potential benefit of their use. Results
actually demonstrated high rates of vasopressor-induced complications, with 70% of patients
experiencing an associated complication including tachycardia, (heart rate >130), bradycardia
(heart rate < 50), ventricular tachycardia, elevated troponins, new onset atrial fibrillation, atrial
flutter, skin necrosis, electrocardiogram (ECG) changes, ST changes consistent with ischemia,
and acidosis (pH <7.0). These clinical findings should bring pause to the clinical decision to
utilize vasopressors for hypertensive therapy and likely contribute to increased length of stay and
patient hemodynamic instability. Future studies would need to incorporate new parameters
including length of stay and morbidity analysis to more completely elucidate the side effects of
vasopressor use in this patient population.
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Another study calling into question the efficacy of vasopressors to maintain arbitrarily set

values is a review article by Martin et al. (2015). Their group hypothesized that increased MAP
goals and episodes of relative hypotension do not affect hospital outcomes. Their group theorized
that poor outcomes are a byproducts of SCI severity and are independent of MAP maintenance.
The findings seem to support their suspicion. Of note, this is the largest published cohort of acute
SCI patients and evaluation of functional outcomes as it relates to set MAP goals during
hospitalization giving it added quantitative power when compared to other studies. 105 cervical
and thoracic SCI patients treated at a level one trauma and regional SCI center over a 2.5 year
period were retrospectively reviewed with the lowest and average hourly MAP recorded for the
first 72 hours of hospitalization. The authors used the American Spinal Injury Associations
Motor Score (AMS) to determine severity of injury. AMS is a more complex scoring system then
the ASIA as it allows for each limb to be scored separately instead of upper vs lower extremities.
AMS is calculated by assessing function in 5 key muscle groups per extremity, and each muscle
group has a maximum score of 5, creating a maximum score of 100. They found that at higher
theoretic MAP set points (85 and 90) there were increased numbers of relative hypotensive
episodes and lower ASIA scores, and therefore an increased need for vasopressors (P=0.03).
They did not however show a statistical change in AMS by hospital discharge that matched with
patients receiving vasopressors. Instead the need for vasopressors correlated with the number of
hypotensive episodes and was inversely related to admission AMS.
They concluded based on this data that the frequency of relative hypotension and the
need for vasopressors was related to severity of SCI and not the independent use of vasopressors.
These episodes of hypotension and need for vasopressors did not affect the change in AMS
during the acute hospitalization.
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improve outcomes following penetrating spinal cord injury. While this is a technically unique
subgroup of patients (penetrating trauma only), it does show that hypertensive management may
not be appropriate in all cases of spinal cord injury. This study was performed at the brain and
spinal injury center through the university of California, San Francisco, and included 14 patients
with complete penetrating SCI’s with an admission grade A (no motor or sensory function below
level of injury) American Spinal Injury Association injury admitted from 2005-2011. This small
cohort was compared to a group of 22 SCI patients involving blunt mechanism of injury. Both
groups had complete injuries as indicated by ASIA grade of A (See appendix A). The two groups
were compared in terms of neurological recovery, complications, interventions, and vasopressor
administration. All patients received hypertensive therapy with vasopressors for an average time
of 101.07 hours (±34.96) hours.
Of the 14 penetrating injury patients, only 1 experienced any neurological recovery as
determined by improvement in the American spinal injury association grade. Additionally,
71.43% of these patients with penetrating injuries experienced cardiogenic complications that
may negate any benefit of hypertensive therapy. For comparison, in the blunt injury group there
was improvement based on ASIA score in 8 of 22 patients. The study concludes that penetrating
trauma may be a unique subgroup that is unlikely to benefit from supraphysiologic MAP therapy
due to the more damaging nature of the injury and that more studies will have to be performed to
provide a larger N number for study.
Another area of potential concern is the use of augmented MAP therapy in patients who
are already hypertensive (HTN) at baseline. Kepler et al. (2015) conducted a retrospective casecontroled trial where he highlights that chronic HTN is an independent risk factor for poor
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neurologic recovery. In this study, the authors highlight the autoregulatory physiology of blood
flow to various organs and speculate that goal MAP of 85-90 may be inadequate for enhanced
perfusion in these patients. 92 patents were gathered from a single regional SCI center between

2006 and 2009 that underwent HTN therapy in the intensive care unit for a minimum of 5 days.
Patients were then stratified based on the presence of preexisting HTN. Statistically significant
differences were evaluated by conducting inferential statistical analysis using chi-Square test or
fisher’s test for categorical variable comparisons and the students t-test. Of the 92 patients
included only 22 met criteria for history of HTN. All patients had a target MAP >85, though only
52.6% of the patients with HTN and 46.4% of the patients without HTN had a mean MAP > 85
for 5 complete days post-injury. No difference in mechanism of injury (P=.09), level of spinal
injury (P=.76), gender (P=.1), injury severity score (P=.1), number of patients undergoing
surgery (P=.07), number of patients with a complete SCI (P=.3) was identifiable between the two
cohorts. The only statistically different variable identified between the two groups was the HTN
group was significantly older then the non-HTN group (mean of 70 years old vs. 46.5 years old
respectively). HTN was an independent predictor of poor outcome as patients with HTN had an
average decline in the AMS of 7.6 (100 represents full function). Patients with HTN with an
average MAP that was greater than 85 mm Hg did show a non-statistically significant decrease
in the AMS by 6.4, compared to a decrease of 10.5 for chronic HTN patients with average MAP
<85. While the study numbers are too small to have predictive power, it does support the
hypothesis that higher MAP may need to be utilized for patients with baseline hypertension.

Discussion
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interest for the past several decades, but there is still limited and low-quality evidence regarding
the risks and benefits of this practice. The basis of MAP goals and duration are most commonly
attributed to the study from Vale et al. (1997), which was evaluated above as prospective studies
reporting the goal of elevation of MAP for a specified duration of time post-injury. Elevated
MAP goals are still widely practiced based on a theoretical physiology, other retrospective
reviews, case series, and anecdotal reports. MAP augmentation is also formally recommended by
the AANS/CNS Joint Committee guidelines and will likely continue as a standard of care,
though certain populations may eventually be excluded from the recommendation.
There are risks associated with establishing elevated MAP in the period after SCI, which
include complications due to vasopressor use, invasive monitoring, decreased patient
mobilization, and prolonged hospitalization (Inoue et al, 2014). Some of these risks, in particular
vasopressor use, have been discussed above and display the potential to cause major
complications. Current research is then directed at assessing the risk-benefit profile for
vasopressors, given the lack of definitive high-level evidence of BP augmentation in improving
neurological recovery after SCI.
With regard to the optimal MAP, there have been no direct comparison studies uncovered
by this review that show differences in outcome with different MAP goals. The formal
recommendation of MAP of 85–90 mm Hg appears to be derived from Vale et al. (1997) in
which MAP goals of 85-90 mm Hg were chosen somewhat arbitrarily. There is the possibility
that lower MAP goals may achieve similar results with less risk. Given that BP augmentation is
currently the standard of care after SCI based on current recommendations, future studies in this
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patient population involving control groups will have to carefully consider the potential ethical
questions of providing nonstandard-of-care treatment to a control group.
There is currently a trial investigation that aims to answer the above question: Mean
Arterial Pressure in Spinal Cord Injury (MAPS) trial: Determination of Non-inferiority of a

Mean Arterial Pressure Goal of 65 mm Hg Compared with a Mean Arterial Pressure Goal of 85
mm Hg in Acute Human Traumatic Spinal Cord Injury (clinicaltrials.gov no. NCT02232165).
This study is ongoing at the University of Texas Health Science Center in San Antonio and the
University of Calgary in Alberta. Result from this study may reinforce or alter the AANS/CNS
joint commission guidelines.
The duration of maintaining elevated MAP is currently recommended at 7 days, although
no studies have compared different durations. A number of retrospective articles included here
have reported pursuing elevated MAP goals for a total of 5 days and did not indicate adverse
outcomes related to this duration. This may also change guidelines with future studies.
Recommended vasopressors for BP augmentation in SCI patients have varied but seem to
favor phenylephrine for middle to low thoracic injuries and dopamine for high thoracic and
cervical injuries, given its alpha and beta adrenergic effect (Streijger et al, 2018). Norepinephrine
has been used in recent studies, but its use over dopamine seems to be facility specific. Several
studies here indicate that norepinephrine is superior to dopamine in the treatment of spinal shock,
and that recommendation is backed by the AANS in their official recommendations (Readdy, W.
Dhall, S. 2016).
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injury) was not associated with improvement in one study (Catapano et al, 2016) and further
study may show that these less severe injuries do not require supraphysiologic MAP.
Readdy and Dhall wrote an excellent review in Neural Regeneration Research (2016)
titled Vasopressor administration in spinal cord injury: Should we apply a universal standard to
all injury patterns? In it they review many of the above studies and emphasize that SCI is often
treated as a homogenous injury pattern, despite the wide variations in injury and outcomes. Level
of injury, mechanism of injury, presence of hemorrhagic spinal cord trauma, and pattern of
intraspinal injury can all influence the results and may need to be considered independently to
MAP. The advocate for clinical decision-making and judicious use of augmented MAP in some
cases.

Limitations
This review of articles pertaining to supraphysiologic MAP maintenance and neurologic
recovery in SCI patients is significantly limited by a number of important factors. At the
individual study level, there were often low numbers of patients, follow-up was often limited,
and almost all of the studies lacked comparison groups. These limitations are particularly
relevant when studying neural regeneration as improvements in function can still occur years
after the initial injury. Across each study, there were variations in MAP goals and outcome
measures, and protocols differed significantly. At the review level, there exists the potential that
this search did not uncover all relevant research, specifically articles not published in English.

VASOPRESSOR SELECTION IN SPINAL CORD INJURY

24

Additionally there is significant possibility of reporting bias and the potential for not reporting all
significant published information, as this literature review was conducted by one researcher. A
complete review would require peer review and additional search criteria spanning non-English
databases.
Conclusions
BP management in the acute period following SCI is an intervention of significant
importance given the severe morbidity associated with SCI. Unfortunately, there is limited highquality evidence to guide BP management, and further research is essential. Based on included
prospective and retrospective studies, which provide the highest level of evidence available, The
AANS does provide the following level III recommendation: MAP goals of 85–90 mm Hg for 5–
7 days post injury should be considered. With regard to the optimal vasopressor, dopamine
should be avoided. Norepinephrine should be considered as a first-line agent for cervical and
upper thoracic SCIs, given evidence that it has a lower risk profile than dopamine. For SCIs in
the mid- to lower thoracic spine, norepinephrine or phenylephrine should be considered as firstline agents.
Blood pressure management is just one of a multitude of interventions in the acute phase
of injury, but it’s importance as even a minor contributor to overall recovery should not be
overlooked as the function preserved for future patients could result in significant improvements
in quality of life and hope for recovery.
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